S&P 500   2,997.95 (+0.28%)
DOW   27,025.88 (+0.09%)
QQQ   193.41 (+0.19%)
AAPL   234.33 (-0.02%)
FB   189.67 (+0.06%)
MSFT   139.47 (-0.67%)
GOOGL   1,253.85 (+0.87%)
AMZN   1,790.38 (+0.73%)
CGC   20.31 (+2.94%)
NVDA   192.60 (-0.83%)
MU   45.44 (+0.62%)
BABA   176.24 (-0.50%)
GE   9.07 (+1.80%)
TSLA   262.42 (+1.03%)
AMD   31.02 (+0.68%)
T   37.78 (-0.03%)
F   9.10 (+0.33%)
ACB   3.80 (+5.27%)
PRI   123.96 (+0.07%)
NFLX   293.35 (+2.47%)
BAC   30.07 (-0.33%)
GILD   65.16 (-0.29%)
DIS   132.86 (+1.53%)
S&P 500   2,997.95 (+0.28%)
DOW   27,025.88 (+0.09%)
QQQ   193.41 (+0.19%)
AAPL   234.33 (-0.02%)
FB   189.67 (+0.06%)
MSFT   139.47 (-0.67%)
GOOGL   1,253.85 (+0.87%)
AMZN   1,790.38 (+0.73%)
CGC   20.31 (+2.94%)
NVDA   192.60 (-0.83%)
MU   45.44 (+0.62%)
BABA   176.24 (-0.50%)
GE   9.07 (+1.80%)
TSLA   262.42 (+1.03%)
AMD   31.02 (+0.68%)
T   37.78 (-0.03%)
F   9.10 (+0.33%)
ACB   3.80 (+5.27%)
PRI   123.96 (+0.07%)
NFLX   293.35 (+2.47%)
BAC   30.07 (-0.33%)
GILD   65.16 (-0.29%)
DIS   132.86 (+1.53%)
Log in

Fennec Pharmaceuticals Stock Price, News & Analysis (NASDAQ:FENC)

$4.52
-0.09 (-1.95 %)
(As of 10/17/2019 04:00 PM ET)
Today's Range
$4.48
Now: $4.52
$4.85
50-Day Range
$4.15
MA: $4.61
$4.96
52-Week Range
$3.26
Now: $4.52
$8.23
Volume8,874 shs
Average Volume60,897 shs
Market Capitalization$89.93 million
P/E RatioN/A
Dividend YieldN/A
Beta0.08
Fennec Pharmaceuticals Inc, a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children. The company was formerly known as Adherex Technologies Inc and changed its name to Fennec Pharmaceuticals Inc in September 2014. Read More…

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:FENC
CUSIPN/A
Phone919-636-4530

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$1.07 per share

Profitability

Net Income$-9,890,000.00

Miscellaneous

EmployeesN/A
Market Cap$89.93 million
Next Earnings Date11/12/2019 (Estimated)
OptionableOptionable

Receive FENC News and Ratings via Email

Sign-up to receive the latest news and ratings for FENC and its competitors with MarketBeat's FREE daily newsletter.


Fennec Pharmaceuticals (NASDAQ:FENC) Frequently Asked Questions

What is Fennec Pharmaceuticals' stock symbol?

Fennec Pharmaceuticals trades on the NASDAQ under the ticker symbol "FENC."

How were Fennec Pharmaceuticals' earnings last quarter?

Fennec Pharmaceuticals Inc (NASDAQ:FENC) released its quarterly earnings data on Friday, August, 9th. The company reported ($0.24) EPS for the quarter, missing the consensus estimate of ($0.14) by $0.10. View Fennec Pharmaceuticals' Earnings History.

When is Fennec Pharmaceuticals' next earnings date?

Fennec Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Tuesday, November 12th 2019. View Earnings Estimates for Fennec Pharmaceuticals.

What price target have analysts set for FENC?

2 analysts have issued 12 month target prices for Fennec Pharmaceuticals' shares. Their forecasts range from $16.00 to $17.00. On average, they expect Fennec Pharmaceuticals' stock price to reach $16.50 in the next year. This suggests a possible upside of 265.0% from the stock's current price. View Analyst Price Targets for Fennec Pharmaceuticals.

What is the consensus analysts' recommendation for Fennec Pharmaceuticals?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Fennec Pharmaceuticals in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Fennec Pharmaceuticals.

What are Wall Street analysts saying about Fennec Pharmaceuticals stock?

Here are some recent quotes from research analysts about Fennec Pharmaceuticals stock:
  • 1. According to Zacks Investment Research, "Fennec Pharmaceuticals Inc. is a clinical-stage biotechnology company. It is focused on the development of Sodium Thiosulfate for the prevention of ototoxicity from cisplatin in pediatric patients. The Company's products include Eniluracil and Sodium Thiosulfate (STS). Fennec Pharmaceuticals Inc., formerly known as Adherex Technologies Inc., is based in United States. " (10/14/2019)
  • 2. HC Wainwright analysts commented, "In our view, PEDMARK is worth roughly $430M to Fennec based on a risk-adjusted net present value (NPV) calculation that employs a 12% discount rate, 85% probability of success and a 26% effective tax rate." (12/10/2018)

Has Fennec Pharmaceuticals been receiving favorable news coverage?

News coverage about FENC stock has been trending very negative this week, InfoTrie Sentiment Analysis reports. The research firm identifies positive and negative media coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Fennec Pharmaceuticals earned a daily sentiment score of -3.1 on InfoTrie's scale. They also gave headlines about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the stock's share price in the next several days. View News Stories for Fennec Pharmaceuticals.

Who are some of Fennec Pharmaceuticals' key competitors?

What other stocks do shareholders of Fennec Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Fennec Pharmaceuticals investors own include Iovance Biotherapeutics (IOVA), Allena Pharmaceuticals (ALNA), Amarin (AMRN), Fate Therapeutics (FATE), Coherus Biosciences (CHRS), Denali Therapeutics (DNLI), Exelixis (EXEL), Amicus Therapeutics (FOLD), Obseva (OBSV) and Pieris Pharmaceuticals (PIRS).

Who are Fennec Pharmaceuticals' key executives?

Fennec Pharmaceuticals' management team includes the folowing people:
  • Mr. Rostislav Raykov, Pres, CEO & Director (Age 42)
  • Mr. Robert C. Andrade, Chief Financial Officer (Age 43)
  • Mr. Mark Gowland, Controller
  • Mr. Lei Fang, Pres of Pharstat Inc
  • Ms. Anne McKay, Regulatory Consultant (Age 64)

Who are Fennec Pharmaceuticals' major shareholders?

Fennec Pharmaceuticals' stock is owned by many different of institutional and retail investors. Top institutional shareholders include Wedbush Securities Inc. (0.06%). Company insiders that own Fennec Pharmaceuticals stock include Manchester Management Pr, Llc and Spa Essetifin. View Institutional Ownership Trends for Fennec Pharmaceuticals.

Which major investors are buying Fennec Pharmaceuticals stock?

FENC stock was purchased by a variety of institutional investors in the last quarter, including Wedbush Securities Inc.. View Insider Buying and Selling for Fennec Pharmaceuticals.

How do I buy shares of Fennec Pharmaceuticals?

Shares of FENC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Fennec Pharmaceuticals' stock price today?

One share of FENC stock can currently be purchased for approximately $4.52.

How big of a company is Fennec Pharmaceuticals?

Fennec Pharmaceuticals has a market capitalization of $89.93 million. The company earns $-9,890,000.00 in net income (profit) each year or ($0.50) on an earnings per share basis. View Additional Information About Fennec Pharmaceuticals.

What is Fennec Pharmaceuticals' official website?

The official website for Fennec Pharmaceuticals is http://www.fennecpharma.com/.

How can I contact Fennec Pharmaceuticals?

Fennec Pharmaceuticals' mailing address is PO BOX 13628 68 TW ALEXANDER DRIVE, DURHAM NC, 27709. The company can be reached via phone at 919-636-4530.


MarketBeat Community Rating for Fennec Pharmaceuticals (NASDAQ FENC)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  122 (Vote Outperform)
Underperform Votes:  128 (Vote Underperform)
Total Votes:  250
MarketBeat's community ratings are surveys of what our community members think about Fennec Pharmaceuticals and other stocks. Vote "Outperform" if you believe FENC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe FENC will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 10/17/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel